Tianjin Chase Sun Pharmaceutical Co.,Ltd cancelled the acquisition of additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million.
January 18, 2021
Share
Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) intends to acquire additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million on January 20, 2020. Post completion, Tianjin Chase Sun Pharmaceutical Co.,Ltd will hold 75.92% stake in Hubei Enoray Biopharmaceutical Co., Ltd. The transaction was approved on January 20, 2020 by the 5th meeting of the 7th Directorate. As of September 30, 2019, Hubei Enoray Biopharmaceutical Co., Ltd. has total assets of CNY 223.5 million and owners equity of CNY 168.2 million.
Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) cancelled the acquisition of additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million on January 19, 2021.
Tianjin Chase Sun Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company's main products include Chinese traditional formula granules, Xuebijing injection, fasudil hydrochloride injection, low molecular weight heparin calcium injection, bulk drugs and excipient, among others. The Company also provides medical apparatus and instrument. The Company distributes its products in domestic market and to overseas markets.
Tianjin Chase Sun Pharmaceutical Co.,Ltd cancelled the acquisition of additional 25% stake in Hubei Enoray Biopharmaceutical Co., Ltd. from Hubei Wurui Biotechnology Co., Ltd. for CNY 60 million.
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD 
